The federal government has taken its most concrete step toward rescheduling cannabis in decades, and the compliance clock for state-licensed medical operators is already ticking. A Department of Justice Final Order has placed cannabis subject to a state medical marijuana license into Schedule III of the Controlled Substances Act - a move with immediate consequences for DEA registration, federal tax treatment under Section 280E, and potential retrospective relief from Treasury. Separately, the DEA has initiated formal hearing proceedings on the broader proposed rescheduling of all marijuana from Schedule I to Schedule III, with those proceedings set to commence June 29, 2026.
What the DOJ Final Order Actually Changes for Medical Operators
The distinction between the DOJ's Final Order and the DEA's ongoing broader rescheduling proceeding matters more than most headlines suggest. The Final Order specifically targets cannabis operations that operate under a state medical marijuana license - it does not yet extend to adult-use operators. For those medical cannabis businesses, the practical implications are immediate and layered.
First, DEA registration. Schedule III substances require federal registration with the DEA for manufacturers, distributors, and dispensers. State-licensed medical operators who have existed entirely outside the federal scheduling framework now face a question they've never had to answer: what does federal registration look like in practice, what timelines apply, and what compliance obligations does it trigger? The regulatory infrastructure for this registration process is still being worked out - which is precisely the kind of ambiguity that creates legal and operational risk.
Second, and more immediately felt at the business level, is Section 280E. That provision of the Internal Revenue Code prohibits businesses trafficking in Schedule I or Schedule II substances from deducting ordinary business expenses - payroll, rent, marketing - from federal taxable income. The result has been tax bills that bear no resemblance to what a comparably sized retail or manufacturing operation would owe. Moving to Schedule III removes cannabis from 280E's scope for covered operators. For a medical dispensary carrying real estate costs, significant payroll, and wholesale purchasing, that shift can represent a material change in effective tax rate. The exact magnitude depends on each operator's cost structure, but the directional impact is unambiguous.
Third - and here's where it gets genuinely interesting - Treasury is reportedly considering retrospective relief. If that materializes, operators who overpaid federal taxes under 280E during periods when their operations should have been eligible for Schedule III treatment could have a path to recovery. The parameters of that potential relief, eligibility criteria, and process are not yet defined. Tax advisors with cannabis clients should be watching this closely and advising clients to maintain meticulous records in the interim.
Legal Challenges Are Already Forming
The Final Order is not arriving without opposition. Legal challenges to the DOJ's action are emerging, and they raise procedurally and substantively serious questions about the authority underlying the order, its scope, and whether the rulemaking process was properly conducted. That's not unusual for an action of this magnitude - but it does mean that operators and their counsel should treat the current situation as legally unsettled, not resolved.
In practice, that means medical cannabis operators should avoid making irreversible compliance or financial decisions based solely on the Final Order until the legal picture clarifies. Engage qualified cannabis regulatory counsel. Document everything. And resist the urge to assume that because the federal posture has shifted, all prior risk has evaporated. It hasn't.
The Broader DEA Hearing and What It Means for Adult-Use Operators
The DEA's June 2026 hearing proceedings address something larger: a formal rescheduling proposal covering all marijuana, not just state-licensed medical cannabis. Adult-use operators - dispensaries, vertically integrated multi-state operators, cultivators, processors - have been watching the medical-specific Final Order with understandable frustration. They remain, for now, outside its immediate scope.
The hearing process is formal administrative procedure. It is not a quick pivot. The DEA will hear evidence and testimony, parties will file briefs, and a recommended decision will eventually work its way through the administrative law process before any rule becomes final. The June 2026 commencement date signals that this will extend well into the latter half of the decade before producing final federal rulemaking that adult-use operators can rely on operationally.
That's a long runway, but it's not a reason to disengage. Multi-state operators with both medical and adult-use licenses in the same or different states face a particularly complex situation: portions of their business may fall under the Final Order's scope while other portions do not. The interplay between state licensing classifications, federal registration requirements, and 280E treatment will require careful entity-level analysis, not a blanket assumption.
What Operators and Advisors Should Do Before the Dust Settles
The honest answer is that no one has a complete map here yet. Federal cannabis rescheduling - in any form - is genuinely novel territory, and the compliance architecture is being built in real time alongside legal challenges, administrative proceedings, and regulatory guidance that has not yet been issued. That's uncomfortable. It's also the operational reality.
A few concrete priorities stand out regardless:
- State-licensed medical operators should assess whether their license structure qualifies them under the Final Order and consult federal regulatory counsel on DEA registration timelines and obligations.
- Tax advisors should begin modeling the 280E impact on current and prior-year returns for eligible clients, and flag the Treasury retrospective relief question for ongoing monitoring.
- Adult-use operators and multi-state businesses should map their entity structures and license classifications now, well before the June 2026 DEA hearings produce any binding outcome.
- All stakeholders should watch the legal challenges to the Final Order; a successful challenge could reset the timeline and scope significantly.
The federal posture on cannabis has shifted more in recent months than it did in the prior decade. That's not a reason for complacency - it's a reason to be prepared.
